Cybin Inc CYBN:NYSE American

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/10/24 EDT
0.35quote price arrow down-0.0124 (-3.4207%)
Volume
94,842
Close
0.3625quote price arrow down-0.0113 (-3.023%)
Volume
4,351,244
52 week range
0.21 - 0.74
Loading...
  • Open0.38
  • Day High0.38
  • Day Low0.3422
  • Prev Close0.3738
  • 52 Week High0.74
  • 52 Week High Date10/31/23
  • 52 Week Low0.21
  • 52 Week Low Date06/06/23

Key Stats

  • Market Cap270.13M
  • Shares Out759.69M
  • 10 Day Average Volume2.59M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-11.59

KEY STATS

  • Open0.38
  • Day High0.38
  • Day Low0.3422
  • Prev Close0.3738
  • 52 Week High0.74
  • 52 Week High Date10/31/23
  • 52 Week Low0.21
  • 52 Week Low Date06/06/23
  • Market Cap270.13M
  • Shares Out759.69M
  • 10 Day Average Volume2.59M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-11.59

RATIOS/PROFITABILITY

  • EPS (TTM)-0.21
  • P/E (TTM)-1.70
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date06/24/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Cybin Inc

 

Profile

MORE
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and...
Eric So
Executive Chairman of the Board, President, Co-founder
Douglas Drysdale
Chief Executive Officer
Greg Cavers
Chief Financial Officer
Address
100 King Street West, Suite 5600
Toronto, ON
M5X 1C9
Canada